Nuvl is the official Nasdaq stock exchange ticker symbol for Nuvalent, Inc., a specialized clinical-stage biopharmaceutical enterprise focused on designing and developing precision-targeted small-molecule therapies for cancer patients. The company utilizes advanced structure-based drug design to engineer innovative medicines that overcome treatment resistance and address brain metastases in genomically defined tumors, prior to its acquisition by GSK.